adalimumab (Humira)

in the absence of a submission from the holder of the marketing authorisation:

adalimumab (Humira®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.  (This licence extension relates to previous SMC advice (468/08).

SMC has previously accepted adalimumab for restricted use for the treatment of chronic plaque psoriasis in adult patients who failed to respond to or have a contraindication to, or are intolerant to other systemic therapy including ciclosporin, methotrexate or PUVA. It is restricted to patients with severe disease as defined by a total Psoriasis Area Severity Index score of ≥10 and a Dermatology Life Quality Index of >10. (SMC 468/08).  This advice remains valid.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting.  As a result we cannot recommend its use within NHSScotland.